Jinfeng Chen retweeted
1/8 Our new paper w/ @CaixiaGaoLab & @GogoLiu groups reveals how #CRISPR-Cas12 systems evolved from transposon-encoded TnpB nucleases through RNA splitting by analyzing “TranC” systems ( evolutionary intermediates bridging selfish elements and adaptive immunity). #Evolution
Now online! Functional RNA splitting drove the evolutionary emergence of type V CRISPR-Cas systems from transposons dlvr.it/TNMWkR
Jinfeng Chen retweeted
Talks by:
@GonzalezLab_BCN
Yalong Guo
Axel Meyer
Emmanuelle Lerat
Cheng Sun
Qiheng Xu
Jie Cui
@ilyavkirov
Chengyi Song
Li Wang
@JingWang368
@KoflerRobert
Ying Liu
@clamp131
Jinfeng Chen retweeted
#SMBE2025 Symposium 15: Transposable elements in genome evolution and biotechnology development
🔗 smbe2025.scimeeting.cn/en/we…
Jinfeng Chen retweeted
📣TE meeting in China (Apr. 7-11)❗️
1. Great Science from worldwide🌏
2. Easy transportation from Shanghai
3. Awesome Chinese food 🥘 🥟
4. Inexpensive costs for meeting and traveling
5. Meet friends/colleagues/editor
csh-asia.org/?content/2544
Jinfeng Chen retweeted
🧨📣ecDNA, eccDNA, cccDNA, double minutes. I know, it’s confusing…😉
Let’s get together regardless of nomenclature🍻🍻
Join us if you study DNA circles from plants, yeasts, worms, viruses, transposons, & of course, tumors!🥂🥂
Awesome venue + fabulous science🥳
🧬🌟We're excited to add an Extrachromosomal Circular DNA conference to our 2025 calendar!🧬🌟
Chairs Birgitte Regenberg (Univ. of Copenhagen) & Zhao Zhang (Duke Univ.) are bringing a fantastic line up of speakers together in Mexico this November. More details➡️bit.ly/4az0PbV #ecDNA25 #eccDNA #ecDNA @zz_zhaozhang @B_Regenberg
The deadline for submitting an abstract for the TE symposium at SMBE 2025 is approaching (January 30). Please join us if you want to share your research and enjoy the culture in Beijing. @OfficialSMBE, @pkuzhangy @CedricFeschotte @zz_zhaozhang @MobDNAjournal #SMBE
Our invited speaker is Dr. Josefa González, @GonzalezLab_BCN. We will be ready to welcome you all in Beijing.
48
Excited to present our work on the evolution of transposable element activity in San Diego. Thank you so much for Jungnam and the ICAR committee for the invitation.
I am glad to share our latest work in collaboration with Dr. Yi Sui on the establishment of genome-editing system in broomcorn millet (doi.org/10.1111/jipb.13664). It is a series of works since we have been working on this orphan crop.
1/4
Recently, in collaborate with Dr. Xianmin Diao, we studied transposable element-mediated structure variations in broomcorn millet and foxtail millet using pangenome approaches (nature.com/articles/s41588-0… and nature.com/articles/s41588-0…).
3/4
5
189
In an earlier study, in collaboration with Dr. Mingsheng Chen, we resolved two subgenomes of the tetraploid genome of broomcorn millet and found that biased mutations and gene losses occurred during the diploidization of its genome (onlinelibrary.wiley.com/doi/…).
2/4
3
149
Jinfeng Chen retweeted
A long non-coding RNA with established functions in plant immunity! We wrote a little introduction (doi.org/10.1016/j.chom.2022.…) to this cool paper from Liu et al. (doi.org/10.1016/j.chom.2022.…), who discovered a lncRNA that controls SA biosynthesis, out today in Cell Host & Microbe.
This Post is from an account that no longer exists. Learn more
Jinfeng Chen retweeted
Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy dlvr.it/SBv4yn
Jinfeng Chen retweeted
Our latest work led by Jason Griffiths and Jinfeng Chen exploring convergent mechanisms of resistance to combination cell cycle and endocrine inhibitors in early stage breast cancer is out today in @NatureCancer!
rdcu.be/clSy7
Our paper “Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy” is out! Yes, this is the same Jinfeng studying TE. rdcu.be/clSpC
I worked at City of Hope from 2019 to 2020 with @AndreaBildLab @AndreaBild. We use single-cell RNAseq and WES to profile early stage ER+ breast cancer patients treated with endocrine and/or CDK4/6 inhibitor and reveal why tumors are resistance to combination therapy.
2
















